Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes
Abstract
:1. Introduction
2. Materials and Methods
2.1. Subjects
2.2. Samples
2.3. Sample Preparation
2.4. Statistical Methods
3. Results
3.1. Plasma Levels
3.2. Lymphocyte Levels
4. Discussion
4.1. CoQ10 in Plasma
4.2. Lymphocytes from Peripheral Blood Are Valuable Biological Material for Analysis of Mitochondrial Parameters
4.3. CoQ10 in Lymphocytes
4.4. Possible Causes of Differential Q10 in Parkinson’s Disease Patients
4.5. Correlation of CoQ10 Levels with the Clinical State
4.6. Limitations of the Study
5. Significance of Differential Q10 in Parkinson’s Disease Patients and Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
References
- Gilman, S.; Wenning, G.; Low, P.A.; Brooks, D.; Mathias, C.J.; Trojanowski, J.Q.; Wood, N.; Colosimo, C.; Durr, A.; Fowler, C.J.; et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008, 71, 670–676. [Google Scholar] [CrossRef] [PubMed]
- Jakes, R.; Spillantini, M.G.; Goedert, M. Identification of two distinct synucleins from human brain. FEBS Lett. 1994, 345, 27–32. [Google Scholar] [CrossRef] [PubMed]
- Hashimoto, M.; Rockenstein, E.; Mante, M.; Mallory, M.; Masliah, E. β-Synuclein inhibits α-synuclein aggregation: A possible role as an anti-parkinsonian factor. Neuron 2001, 32, 213–223. [Google Scholar] [CrossRef] [PubMed]
- Askanas, V.; Engel, W.K.; Alvarez, R.B.; McFerrin, J.; Broccolini, A. Novel Immunolocalization of α-Synuclein in Human Muscle of Inclusion-Body Myositis, Regenerating and Necrotic Muscle Fibers, and at Neuromuscular Junctions. J. Neuropathol. Exp. Neurol. 2000, 59, 592–598. [Google Scholar] [CrossRef]
- Shin, E.C.; Cho, S.E.; Lee, D.K.; Hur, M.W.; Paik, S.R.; Park, J.H.; Kim, J. Expression Patterns of α-Synuclein in Human Hematopoietic Cells and in Drosophila at Different Developmental Stages. Mol. Cells 2000, 10, 65–70. [Google Scholar] [CrossRef]
- Baltic, S.; Perovic, M.; Mladenovic, A.; Raicevic, N.; Ruzdijic, S.; Rakic, L.; Kanazir, S. α-synuclein is expressed in different tissues during human fetal development. J. Mol. Neurosci. 2004, 22, 199–203. [Google Scholar] [CrossRef] [PubMed]
- Tamo, W.; Imaizumi, T.; Tanji, K.; Yoshida, H.; Mori, F.; Yoshimoto, M.; Takahashi, H.; Fukuda, I.; Wakabayashi, K.; Satoh, K. Expression of α-synuclein, the precursor of non-amyloid β component of Alzheimer’s disease amyloid, in human cerebral blood vessels. Neurosci. Lett. 2002, 326, 5–8. [Google Scholar] [CrossRef]
- Li, J.; Uversky, V.N.; Fink, A.L. Conformational behavior of human α-synuclein is modulated by familial Parkinson’s disease point mutations A30P and A53T. Neurotoxicology 2002, 23, 553–567. [Google Scholar] [CrossRef] [PubMed]
- Kim, S.; Seo, J.H.; Suh, Y.H. α-synuclein, Parkinson’s disease, and Alzheimer’s disease. Park. Relat. Disord. 2004, 10 (Suppl. 1), S9–S13. [Google Scholar] [CrossRef] [PubMed]
- Uéda, K.; Fukushima, H.; Masliah, E.; Xia, Y.; Iwai, A.; Yoshimoto, M.; Otero, D.A.; Kondo, J.; Ihara, Y.; Saitoh, T. Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA 1993, 90, 11282–11286. [Google Scholar] [CrossRef]
- Nakamura, K.; Nemani, V.M.; Wallender, E.K.; Kaehlcke, K.; Ott, M.; Edwards, R.H. Optical reporters for the conformation of α-synuclein reveal a specific interaction with mitochondria. J. Neurosci. 2008, 28, 12305–12317. [Google Scholar] [CrossRef]
- Monzio Compagnoni, G.; Di Fonzo, A. Understanding the pathogenesis of multiple system atrophy: State of the art and future perspectives. Acta Neuropathol. Commun. 2019, 7, 113. [Google Scholar] [CrossRef] [PubMed]
- Laurens, B.; Vergnet, S.; Lopez, M.C.; Foubert-Samier, A.; Tison, F.; Fernagut, P.O.; Meissner, W.G. Multiple System Atrophy—State of the Art. Curr. Neurol. Neurosci. Rep. 2017, 17, 41. [Google Scholar] [CrossRef] [PubMed]
- Bassil, F.; Canron, M.-H.; Vital, A.; Bezard, E.; Li, Y.; Greig, N.H.; Gulyani, S.; Kapogiannis, D.; Fernagut, P.-O.; Meissner, W.G. Insulin resistance and exendin-4 treatment for multiple system atrophy. Brain 2017, 140, 1420–1436. [Google Scholar] [CrossRef]
- Zhou, L.; Jiang, Y.; Zhu, C.; Ma, L.; Huang, Q.; Chen, X. Oxidative Stress and Environmental Exposures are Associated with Multiple System Atrophy in Chinese Patients. Can. J. Neurol. Sci. 2016, 43, 703–709. [Google Scholar] [CrossRef] [PubMed]
- Foti, S.C.; Hargreaves, I.; Carrington, S.; Kiely, A.P.; Houlden, H.; Holton, J.L. Cerebral mitochondrial electron transport chain dysfunction in multiple system atrophy and Parkinson’s disease. Sci. Rep. 2019, 9, 6559. [Google Scholar] [CrossRef] [PubMed]
- Gu, M.; Gash, M.T.; Cooper, J.M.; Wenning, G.K.; Daniel, S.E.; Quinn, N.P.; Marsden, C.D.; Schapira, A.H.V. Mitochondrial respiratory chain function in multiple system atrophy. Mov. Disord. 1997, 12, 418–422. [Google Scholar] [CrossRef]
- Li, W.-W.; Yang, R.; Guo, J.-C.; Ren, H.-M.; Zha, X.-L.; Cheng, J.-S.; Cai, D.-F. Localization of α-synuclein to mitochondria within midbrain of mice. Neuroreport 2007, 18, 1543–1546. [Google Scholar] [CrossRef]
- Liu, G.; Zhang, C.; Yin, J.; Li, X.; Cheng, F.; Li, Y.; Yang, H.; Uéda, K.; Chan, P.; Yu, S. α-Synuclein is differentially expressed in mitochondria from different rat brain regions and dose-dependently down-regulates complex I activity. Neurosci. Lett. 2009, 454, 187–192. [Google Scholar] [CrossRef]
- Hsu, L.J.; Mallory, M.; Xia, Y.; Veinbergs, I.; Hashimoto, M.; Yoshimoto, M.; Thal, L.J.; Saitoh, T.; Masliah, E. Expression pattern of synucleins (non-Aβ component of Alzheimer’s disease amyloid precursor protein/α-synuclein) during murine brain development. J. Neurochem. 1998, 71, 338–344. [Google Scholar] [CrossRef]
- Junn, E.; Mouradian, M.M. Human α-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci. Lett. 2002, 320, 146–150. [Google Scholar] [CrossRef]
- Winklhofer, K.F.; Haass, C. Mitochondrial dysfunction in Parkinson’s disease. Biochim. Biophys. Acta 2010, 1802, 29–44. [Google Scholar] [CrossRef] [PubMed]
- Bose, A.; Beal, M.F. Mitochondrial dysfunction in Parkinson’s disease. J. Neurochem. 2016, 139 (Suppl. 1), 216–231. [Google Scholar] [CrossRef]
- Büeler, H. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Exp. Neurol. 2009, 218, 235–246. [Google Scholar] [CrossRef]
- Exner, N.; Lutz, A.K.; Haass, C.; Winklhofer, K.F. Mitochondrial dysfunction in Parkinson’s disease: Molecular mechanisms and pathophysiological consequences. EMBO J. 2012, 31, 3038–3062. [Google Scholar] [CrossRef] [PubMed]
- Kopin, I.J.; Markey, S.P. MPTP toxicity: Implications for research in Parkinson’s disease. Annu. Rev. Neurosci. 1988, 11, 81–96. [Google Scholar] [CrossRef]
- Cuenca-Bermejo, L.; Pizzichini, E.; Gonçalves, V.C.; Guillén-Díaz, M.; Aguilar-Moñino, E.; Sánchez-Rodrigo, C.; González-Cuello, A.-M.; Fernández-Villalba, E.; Herrero, M.T. A New Tool to Study Parkinsonism in the Context of Aging: MPTP Intoxication in a Natural Model of Multimorbidity. Int. J. Mol. Sci. 2021, 22, 4341. [Google Scholar] [CrossRef] [PubMed]
- Köllensperger, M.; Geser, F.; Seppi, K.; Stampfer-Kountchev, M.; Sawires, M.; Scherfler, C.; Boesch, S.; Mueller, J.; Koukouni, V.; Quinn, N.; et al. Red flags for multiple system atrophy. Mov. Disord. 2008, 23, 1093–1099. [Google Scholar] [CrossRef] [PubMed]
- Palma, J.A.; Norcliffe-Kaufmann, L.; Kaufmann, H. Diagnosis of multiple system atrophy. Auton. Neurosci. 2018, 211, 15–25. [Google Scholar] [CrossRef]
- Kim, H.J.; Jeon, B.; Fung, V.S.C. Role of Magnetic Resonance Imaging in the Diagnosis of Multiple System Atrophy. Mov. Disord. Clin. Pract. 2017, 4, 12–20. [Google Scholar] [CrossRef] [PubMed]
- Compta, Y.; Giraldo, D.M.; Muñoz, E.; Antonelli, F.; Fernández, M.; Bravo, P.; Soto, M.; Cámara, A.; Torres, F.; Martí, M.J.; et al. Cerebrospinal fluid levels of coenzyme Q10 are reduced in multiple system atrophy. Parkinsonism Relat. Disord. 2018, 46, 16–23. [Google Scholar] [CrossRef]
- Mitsui, J.; Tsuji, S. Plasma Coenzyme Q10 Levels and Multiple System Atrophy-Reply. JAMA Neurol. 2016, 73, 1499–1500. [Google Scholar] [CrossRef]
- Schottlaender, L.V.; Bettencourt, C.; Kiely, A.P.; Chalasani, A.; Neergheen, V.; Holton, J.L.; Hargreaves, I.; Houlden, H. Coenzyme Q10 Levels Are Decreased in the Cerebellum of Multiple-System Atrophy Patients. PLoS ONE 2016, 11, e0149557. [Google Scholar] [CrossRef] [PubMed]
- Lagendijk, J.; Ubbink, J.B.; Vermaak, W.J. Measurement of the ratio between the reduced and oxidized forms of coenzyme Q10 in human plasma as a possible marker of oxidative stress. J. Lipid Res. 1996, 37, 67–75. [Google Scholar] [CrossRef] [PubMed]
- Federoff, M.; Schottlaender, L.V.; Houlden, H.; Singleton, A. Multiple system atrophy: The application of genetics in understanding etiology. Clin. Auton. Res. 2015, 25, 19–36. [Google Scholar] [CrossRef] [PubMed]
- Payan, C.A.; Viallet, F.; Landwehrmeyer, B.G.; Bonnet, A.-M.; Borg, M.; Durif, F.; Lacomblez, L.; Bloch, F.; Verny, M.; Fermanian, J.; et al. Disease severity and progression in progressive supranuclear palsy and multiple system atrophy: Validation of the NNIPPS—Parkinson Plus Scale. PLoS ONE 2011, 6, e22293. [Google Scholar] [CrossRef] [PubMed]
- Wenning, G.K.; Tison, F.; Seppi, K.; Sampaio, C.; Diem, A.; Yekhlef, F.; Ghorayeb, I.; Ory, F.; Galitzky, M.; Scaravilli, T.; et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov. Disord. 2004, 19, 1391–1402. [Google Scholar] [CrossRef]
- Hoglinger, G.U.; Respondek, G.; Stamelou, M.; Kurz, C.; Josephs, K.A.; Lang, A.E.; Mollenhauer, B.; Müller, U.; Nilsson, C.; Whitwell, J.L.; et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 2017, 32, 853–864. [Google Scholar] [CrossRef]
- Golbe, L.I.; Ohman-Strickland, P.A. A clinical rating scale for progressive supranuclear palsy. Brain 2007, 130, 1552–1565. [Google Scholar] [CrossRef]
- Askeland, G.; Dosoudilova, Z.; Rodinova, M.; Klempir, J.; Liskova, I.; Kuśnierczyk, A.; Bjørås, M.; Nesse, G.; Klungland, A.; Hansikova, H.; et al. Increased nuclear DNA damage precedes mitochondrial dysfunction in peripheral blood mononuclear cells from Huntington’s disease patients. Sci. Rep. 2018, 8, 9817. [Google Scholar] [CrossRef]
- Krizova, J.; Hulkova, M.; Capek, V.; Mlejnek, P.; Silhavy, J.; Tesarova, M.; Zeman, J.; Hansikova, H. Microarray and qPCR Analysis of Mitochondrial Metabolism Activation during Prenatal and Early Postnatal Development in Rats and Humans with Emphasis on CoQ(10) Biosynthesis. Biology 2021, 10, 418. [Google Scholar] [CrossRef] [PubMed]
- Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265–275. [Google Scholar] [CrossRef]
- Srere, P.A. [1] Citrate synthase. [EC 4.1.3.7. Citrate oxaloacetate-lyase (CoA-acetylating)]. Methods Enzymol. 1969, 13, 3–11. [Google Scholar]
- Mosca, F.; Fattorini, D.; Bompadre, S.; Littarru, G.P. Assay of coenzyme Q(10) in plasma by a single dilution step. Anal. Biochem. 2002, 305, 49–54. [Google Scholar] [CrossRef]
- Du, J.; Wang, T.; Huang, P.; Cui, S.; Gao, C.; Lin, Y.; Fu, R.; Shen, J.; He, Y.; Tan, Y.; et al. Clinical correlates of decreased plasma coenzyme Q10 levels in patients with multiple system atrophy. Parkinsonism Relat. Disord. 2018, 57, 58–62. [Google Scholar] [CrossRef] [PubMed]
- Jenner, P. Oxidative stress in Parkinson’s disease. Ann. Neurol. 2003, 53 (Suppl. 3), S26–S36, discussion S36–S38. [Google Scholar] [CrossRef]
- Dias, V.; Junn, E.; Mouradian, M.M. The role of oxidative stress in Parkinson’s disease. J. Parkinsons Dis. 2013, 3, 461–491. [Google Scholar] [CrossRef]
- Mantle, D.; Dybring, A. Bioavailability of Coenzyme Q(10): An Overview of the Absorption Process and Subsequent Metabolism. Antioxidants 2020, 9, 386. [Google Scholar] [CrossRef] [PubMed]
- Kasai, T.; Tokuda, T.; Ohmichi, T.; Ishii, R.; Tatebe, H.; Nakagawa, M.; Mizuno, T. Serum Levels of Coenzyme Q10 in Patients with Multiple System Atrophy. PLoS ONE 2016, 11, e0147574. [Google Scholar] [CrossRef] [PubMed]
- Kuo, S.H.; Quinzii, C.M. Coenzyme Q10 as a Peripheral Biomarker for Multiple System Atrophy. JAMA Neurol. 2016, 73, 917–919. [Google Scholar] [CrossRef]
- Leoni, V.; Caccia, C. Oxysterols as biomarkers in neurodegenerative diseases. Chem. Phys. Lipids 2011, 164, 515–524. [Google Scholar] [CrossRef] [PubMed]
- Dorst, J.; Kühnlein, P.; Hendrich, C.; Kassubek, J.; Sperfeld, A.D.; Ludolph, A.C. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 2011, 258, 613–617. [Google Scholar] [CrossRef]
- D’Amico, E.; Grosso, G.; Nieves, J.W.; Zanghì, A.; Factor-Litvak, P.; Mitsumoto, H. Metabolic Abnormalities, Dietary Risk Factors and Nutritional Management in Amyotrophic Lateral Sclerosis. Nutrients 2021, 13, 2273. [Google Scholar] [CrossRef] [PubMed]
- Fu, X.; Wang, Y.; He, X.; Li, H.; Liu, H.; Zhang, X. A systematic review and meta-analysis of serum cholesterol and triglyceride levels in patients with Parkinson’s disease. Lipids Health Dis 2020, 19, 97. [Google Scholar] [CrossRef] [PubMed]
- Gustafson, A.; Elmfeldt, D.; Wilhelmsen, L.; Tibblin, G. Serum lipids and lipoproteins in men after myocardial infarction compared with representative population sample. Circulation 1972, 46, 709–716. [Google Scholar] [CrossRef] [PubMed]
- Kaikkonen, J.; Nyyssönen, K.; Tuomainen, T.P.; Ristonmaa, U.; Salonen, J.T. Determinants of plasma coenzyme Q10 in humans. FEBS Lett. 1999, 443, 163–166. [Google Scholar] [CrossRef] [PubMed]
- Jiménez-Jiménez, F.J.; Molina, J.A.; de Bustos, F.; García-Redondo, A.; Gómez-Escalonilla, C.; Martínez-Salio, A.; Berbel, A.; Camacho, A.; Zurdo, M.; Barcenilla, B.; et al. Serum levels of coenzyme Q10 in patients with Parkinson’s disease. J. Neural. Transm. 2000, 107, 177–181. [Google Scholar] [CrossRef]
- Pecina, P.; Houšťková, H.; Mráček, T.; Pecinová, A.; Nůsková, H.; Tesařová, M.; Hansíková, H.; Janota, J.; Zeman, J.; Houštěk, J. Noninvasive diagnostics of mitochondrial disorders in isolated lymphocytes with high resolution respirometry. BBA Clin. 2014, 2, 62–71. [Google Scholar] [CrossRef]
- Fišar, Z.; Hansíková, H.; Křížová, J.; Jirák, R.; Kitzlerová, E.; Zvěřová, M.; Hroudová, J.; Wenchich, L.; Zeman, J.; Raboch, J. Activities of mitochondrial respiratory chain complexes in platelets of patients with Alzheimer’s disease and depressive disorder. Mitochondrion 2019, 48, 67–77. [Google Scholar] [CrossRef]
- Fišar, Z.; Hroudová, J.; Hansíková, H.; Spáčilová, J.; Lelková, P.; Wenchich, L.; Jirák, R.; Zvěřová, M.; Zeman, J.; Martásek, P.; et al. Mitochondrial Respiration in the Platelets of Patients with Alzheimer’s Disease. Curr. Alzheimer. Res. 2016, 13, 930–941. [Google Scholar] [CrossRef]
- Duncan, A.J.; Heales, S.J.; Mills, K.; Eaton, S.; Land, J.M.; Hargreaves, I.P. Determination of coenzyme Q10 status in blood mononuclear cells, skeletal muscle, and plasma by HPLC with di-propoxy-coenzyme Q10 as an internal standard. Clin. Chem. 2005, 51, 2380–2382. [Google Scholar] [CrossRef]
- Rötig, A.; Appelkvist, E.-L.; Geromel, V.; Chretien, D.; Kadhom, N.; Edery, P.; Lebideau, M.; Dallner, G.; Munnich, A.; Ernster, L.; et al. Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet 2000, 356, 391–395. [Google Scholar] [CrossRef] [PubMed]
- Shinde, S.; Pasupathy, K. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson’s disease: Preliminary study. Neurol. India 2006, 54, 390–393. [Google Scholar] [CrossRef] [PubMed]
- Gollapudi, S.; Gupta, S. Reversal of oxidative stress-induced apoptosis in T and B lymphocytes by Coenzyme Q10 (CoQ10). Am. J. Clin. Exp. Immunol. 2016, 5, 41–47. [Google Scholar] [PubMed]
- Monzio Compagnoni, G.; Kleiner, G.; Bordoni, A.; Fortunato, F.; Ronchi, D.; Salani, S.; Guida, M.; Corti, C.; Pichler, I.; Bergamini, C.; et al. Mitochondrial dysfunction in fibroblasts of Multiple System Atrophy. Biochim. Biophys. Acta Mol. Basis. Dis. 2018, 1864, 3588–3597. [Google Scholar] [CrossRef] [PubMed]
- Niklowitz, P.; Menke, T.; Andler, W.; Okun, J.G. Simultaneous analysis of coenzyme Q10 in plasma, erythrocytes and platelets: Comparison of the antioxidant level in blood cells and their environment in healthy children and after oral supplementation in adults. Clin. Chim. Acta 2004, 342, 219–226. [Google Scholar] [CrossRef] [PubMed]
- Littarru, G.P.; Tiano, L. Clinical aspects of coenzyme Q10: An update. Nutrition 2010, 26, 250–254. [Google Scholar] [CrossRef]
- Nakamoto, F.K.; Okamoto, S.; Mitsui, J.; Sone, T.; Ishikawa, M.; Yamamoto, Y.; Kanegae, Y.; Nakatake, Y.; Imaizumi, K.; Ishiura, H.; et al. The pathogenesis linked to coenzyme Q10 insufficiency in iPSC-derived neurons from patients with multiple-system atrophy. Sci. Rep. 2018, 8, 14215. [Google Scholar] [CrossRef]
- Herrera-Vaquero, M.; Heras-Garvin, A.; Krismer, F.; Deleanu, R.; Boesch, S.; Wenning, G.K.; Stefanova, N. Signs of early cellular dysfunction in multiple system atrophy. Neuropathol. Appl. Neurobiol. 2021, 47, 268–282. [Google Scholar] [CrossRef]
- Blin, O.; Desnuelle, C.; Rascol, O.; Borg, M.; Peyro Saint Paul, H.; Azulay, J.-P.; Billè, F.; Figarella, D.; Coulom, F.; Pellissier, J.F.; et al. Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson’s disease and multiple system atrophy. J. Neurol. Sci. 1994, 125, 95–101. [Google Scholar] [CrossRef] [PubMed]
- Ebadi, M.; Govitrapong, P.; Sharma, S.; Muralikrishnan, D.; Shavali, S.; Pellett, L.; Schafer, R.; Albano, C.; Eken, J. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson’s disease. Biol. Signals Recept. 2001, 10, 224–253. [Google Scholar] [CrossRef] [PubMed]
- Alcázar-Fabra, M.; Navas, P.; Brea-Calvo, G. Coenzyme Q biosynthesis and its role in the respiratory chain structure. Biochim. Biophys. Acta 2016, 1857, 1073–1078. [Google Scholar] [CrossRef] [PubMed]
- Multiple-System Atrophy Research Collaboration. Mutations in COQ2 in familial and sporadic multiple-system atrophy. N. Engl. J. Med. 2013, 369, 233–244. [Google Scholar] [CrossRef]
- Guo, J.F.; Zhang, L.; Li, K.; Mei, J.P.; Xue, J.; Chen, J.; Tang, X.; Shen, L.; Hong, J.; Chen, C.; et al. Coding mutations in NUS1 contribute to Parkinson’s disease. Proc. Natl. Acad. Sci. USA 2018, 115, 11567–11572. [Google Scholar] [CrossRef] [PubMed]
- Bleasel, J.M.; Wong, J.H.; Halliday, G.M.; Kim, W.S. Lipid dysfunction and pathogenesis of multiple system atrophy. Acta Neuropathol. Commun. 2014, 2, 15. [Google Scholar] [CrossRef]
- Valentino, R.R.; Heckman, M.G.; Johnson, P.W.; Soto-Beasley, A.I.; Walton, R.L.; Koga, S.; Uitti, R.J.; Wszolek, Z.K.; Dickson, D.W.; Ross, O.A. Association of mitochondrial genomic background with risk of Multiple System Atrophy. Parkinsonism Relat. Disord. 2020, 81, 200–204. [Google Scholar] [CrossRef]
- Mitsui, J.; Koguchi, K.; Momose, T.; Takahashi, M.; Matsukawa, T.; Yasuda, T.; Tokushige, S.-I.; Ishiura, H.; Goto, J.; Nakazaki, S.; et al. Three-Year Follow-Up of High-Dose Ubiquinol Supplementation in a Case of Familial Multiple System Atrophy with Compound Heterozygous COQ2 Mutations. Cerebellum 2017, 16, 664–672. [Google Scholar] [CrossRef] [PubMed]
- Rembold, C.M. Coenzyme Q10 Supplementation in Orthostatic Hypotension and Multiple-System Atrophy: A Report on 7 Cases. Am. J. Med. 2018, 131, 444–446. [Google Scholar] [CrossRef] [PubMed]
- Compta, Y.; Muñoz, E.; Martí, M.J. Ubiquinone, ubiquinol, 4-hydroxybenzoic acid… What ‘coenzyme Q10’ should we care about in multiple system atrophy? Parkinsonism Relat. Disord. 2018, 50, 117–118. [Google Scholar] [CrossRef]
- Distelmaier, F. 4-Hydroxybenzoic acid for multiple system atrophy? Parkinsonism Relat. Disord. 2018, 50, 119–120. [Google Scholar] [CrossRef]
- Perez-Lloret, S.; Flabeau, O.; Fernagut, P.; Traon, A.P.; Rey, M.V.; Foubert-Samier, A.; Tison, F.; Rascol, O.; Meissner, W.G. Current Concepts in the Treatment of Multiple System Atrophy. Mov. Disord. Clin. Pract. 2015, 2, 6–16. [Google Scholar] [CrossRef] [PubMed]
- Colosimo, C.; Pezzella, F.R. The symptomatic treatment of multiple system atrophy. Eur. J. Neurol. 2002, 9, 195–199. [Google Scholar] [CrossRef] [PubMed]
- Levin, J.; Kurz, A.; Arzberger, T.; Giese, A.; Höglinger, G.U. The Differential Diagnosis and Treatment of Atypical Parkinsonism. Dtsch. Arztebl. Int. 2016, 113, 61–69. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Bartošová, T.; Klempíř, J.; Hansíková, H. Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes. Antioxidants 2023, 12, 2104. https://doi.org/10.3390/antiox12122104
Bartošová T, Klempíř J, Hansíková H. Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes. Antioxidants. 2023; 12(12):2104. https://doi.org/10.3390/antiox12122104
Chicago/Turabian StyleBartošová, Tereza, Jiří Klempíř, and Hana Hansíková. 2023. "Coenzyme Q10: A Biomarker in the Differential Diagnosis of Parkinsonian Syndromes" Antioxidants 12, no. 12: 2104. https://doi.org/10.3390/antiox12122104